Navigation Links
Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
Date:11/2/2009

CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of J. Michael Sprafka, MPH, PhD, as Vice President, Kendle Consulting. Dr. Sprafka will provide leadership for and drive the development of integrated product development consulting services to help biopharmaceutical companies accelerate time to market and maximize the long-term commercial value of their products. His focus will be on delivery of best-in-class consulting services for customers in the areas of regulatory affairs and submissions, risk management, epidemiology, pharmacovigilance, signal detection and safety evaluations, among others. Dr. Sprafka has held senior leadership roles in the pharmaceutical and government sectors as well as academia and brings the executive level leadership and analytical expertise needed to meet increasing customer demands and heightened global regulatory requirements. He will be based out of Kendle's global headquarters in Cincinnati and will report to Melanie Bruno, PhD, MBA, Vice President, Regulatory, Site and Medical Affairs.

"I am delighted to welcome Michael to the Kendle team," said Dr. Bruno. "His extensive and diverse experience will significantly enhance our ability to deliver best-in-class regulatory consulting services and risk management capabilities to our customers across Phase I through IV clinical development and beyond. As our customers' products move through the product life cycle, Kendle's Consulting team can assist in conducting sophisticated analyses from ongoing data sources to gain a greater understanding of side effects and adverse events and best reflect the products' safety for the patient."

The addition of Dr. Sprafka strengthens Kendle Consulting, a growing area of the Company dedicated to working with biopharmaceutical companies to optimize their clinical development planning, understand and minimize risk and manage product development and monitoring throughout the product lifecycle. By combining the cumulative expertise of Kendle's broad spectrum of clinical development services, Kendle Consulting matches thought leadership with the specific needs of our customers to maximize the value of their portfolios.

Dr. Sprafka is an epidemiologist with extensive expertise in pharmacovigilance, outcomes research and pharmacoeconomics. He has more than 15 years of senior leadership experience, having served most recently as Senior Director, Pharmacovigilance, Epidemiology and Pharmacoeconomics for Procter & Gamble Pharmaceuticals. Dr. Sprafka also has served as Associate Professor of Epidemiology at the University of Minnesota and as an Epidemiologist at the Minnesota Department of Health. He holds a Bachelor of Arts in biology, a Master of Science in environmental health, a Master of Public Health in epidemiology and a Doctorate in epidemiology from the University of Minnesota.

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

SOURCE Kendle International Inc.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
4. Qforma Appoints Erin McLaughlin as Director, Field Operations
5. VitaminSpice Appoints Dr. Richard F. Seelig as Director
6. Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
9. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
10. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
11. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):